Indogulf announces Q4FY26 earnings call on May 29

1 min read     Updated on 23 May 2026, 11:24 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Indogulf Cropsciences Limited has scheduled a Board Meeting on May 28, 2026, to approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The trading window for insiders remains closed until 48 hours after the results declaration. An earnings conference call is set for May 29, 2026, at 12:30 PM IST, featuring the Managing Director and CFO.

powered bylight_fuzz_icon
40984918

*this image is generated using AI for illustrative purposes only.

Indogulf Cropsciences Limited has scheduled its Board Meeting for Thursday, May 28, 2026, at 3:00 PM IST. The meeting will be held to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026, along with the accompanying audit reports. Additionally, the board may consider any other matter with the consent of the Chair.

In accordance with regulations, the company has informed that the trading window for dealing in equity shares by directors, officers, and designated persons has been closed since April 01, 2026. This window will remain closed until 48 hours after the declaration of the audited financial results for the period ended March 31, 2026.

Earnings Conference Call Details

Subsequent to the Board Meeting, Indogulf Cropsciences Limited will host an earnings conference call to discuss the audited financial results for the quarter and financial year ended March 31, 2026. The call is scheduled for Friday, May 29, 2026, at 12:30 PM IST. Management representatives, including the Managing Director and Chief Financial Officer, will be present to address queries.

Conference Call Schedule

Event Date Time (IST)
Board Meeting May 28, 2026 3:00 PM
Earnings Conference Call May 29, 2026 12:30 PM

Management Representatives

Name Designation
Mr. Sanjay Aggarwal Managing Director
Mr. Manoj Gupta Chief Financial Officer

Conference Dial-In Details

Type Numbers
Universal Access +91 22 6280 1488, +91 22 7115 8869
International Toll Free Hong Kong: 800 964 4448, Singapore: 800 101 2045, USA: 1 866 746 2133, UK: 0 808 101 1573

Participants can join the conference call using the universal access numbers or international toll-free lines provided by the company. Pre-registration is recommended to avoid waiting queues.

How has Indogulf Cropsciences' revenue and profit margin trended over the past three financial years, and what growth trajectory can investors expect for FY2027?

Given the agrochemical sector's sensitivity to monsoon patterns and raw material costs, how might climate variability in 2026 impact Indogulf Cropsciences' near-term earnings outlook?

Are there any planned capital expenditure initiatives, acquisitions, or new product launches that management may announce alongside the FY2026 results?

Indogulf Cropsciences Reports No Deviation in IPO Fund Utilisation for Quarter Ended March 31, 2026

3 min read     Updated on 13 May 2026, 09:51 AM
scanx
Reviewed by
Shraddha JScanX News Team
AI Summary

Indogulf Cropsciences Limited filed its Third Monitoring Agency Report for the quarter ended March 31, 2026, prepared by Brickwork Ratings India Private Limited, confirming no deviation in the utilisation of IPO proceeds from its ₹200 Crore issue. Fund utilisation across all objects — including working capital, borrowing repayment, DF plant capex, general corporate purposes, and issue expenses — was verified by M/s Devesh Parekh & Co., with unutilised proceeds deployed in bank accounts and financial instruments.

powered bylight_fuzz_icon
40110991

*this image is generated using AI for illustrative purposes only.

Indogulf Cropsciences Limited has filed its Third Monitoring Agency Report and Statement of Deviation or Variation for the quarter and year ended March 31, 2026, with BSE Limited and National Stock Exchange of India Limited. The filing, dated May 12, 2026, was made pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. The monitoring report was prepared by Brickwork Ratings India Private Limited, and confirms no deviation or variation in the utilisation of IPO proceeds.

IPO Issue Details

The company raised funds through a Fresh Issue and Offer for Sale of Equity Shares, with allotment completed on July 1, 2025. The issue was open for anchor investors from June 25, 2025 to June 30, 2025, and for other investors from June 25, 2025 to June 26, 2025. The following table summarises the issue details:

Parameter: Details
Issue Type: Fresh Issue and Offer for Sale of Equity Shares
Total Issue Size: ₹200 Crore
Fresh Issue Size: ₹160 Crore
Offer for Sale Size: ₹40 Crore
Issue Price: ₹111 per share
Date of Allotment: July 1, 2025
Monitoring Agency: Brickwork Ratings India Private Limited

The total number of equity shares issued aggregated to 1,80,77,476, comprising 1,44,73,873 shares under the Fresh Issue and 36,03,603 shares under the Offer for Sale. The amount received matched the value as per the Offer Document in both categories.

Fund Utilisation Progress as at March 31, 2026

Brickwork Ratings confirmed that all utilisation is as per the disclosures in the Offer Document, with no material deviation observed. The following table details the progress in utilisation of IPO proceeds across each object:

Item Head: Proposed Amount (₹ Crore) Amount Utilised — End of Quarter (₹ Crore) Unutilised Amount (₹ Crore)
Funding working capital requirements 65.00 68.91 -3.91
Repayment/prepayment of outstanding borrowings 34.12 33.85 0.26
Capital expenditure for DF plant at Barwasni, Sonipat, Haryana 14.00 3.40 10.60
General corporate purposes 27.85 27.25 0.60
Issue expenses 19.03 16.33 2.70

The above details were verified by M/s Devesh Parekh & Co., Chartered Accountants, vide CA certificate dated May 11, 2026, and company statement dated May 11, 2026. It is noted that out of ₹15.38 Crore utilised towards issue expenses for the quarter ended September 30, 2025, the company took reimbursement of ₹2.40 Crore towards issue-related expenses incurred prior to the date of issue.

Deployment of Unutilised Proceeds

Unutilised IPO proceeds have been deployed across bank accounts and financial instruments as at the end of the quarter. The deployment details are as follows:

Instrument / Entity: Amount Invested (₹ Crore) Market Value — End of Quarter (₹ Crore)
Public Offer A/c – 57500001799570 0.00 -
Monitoring A/c – 57500001798899 0.28 -
Invesco India Arbitrage Direct-G 1.12 1.17
Invesco India Arbitrage Reg-G 0.50 0.51
Vivriti Capital Ltd – Commercial Paper (Maturity: April 22, 2026) 9.79 9.94

Implementation Status and Deviation Statement

The monitoring report confirms that no delay has been observed in the implementation of objects relative to the timelines stated in the Offer Document. Working capital funding has been completed, while repayment of borrowings, capital expenditure for the dry flowable (DF) plant at Barwasni, general corporate purposes, and issue expenses remain ongoing, all within the target of Financial Year 2025-26 as per the Offer Document.

The Statement of Deviation or Variation, filed alongside the monitoring report, confirms that there is no deviation or variation in the use of funds raised. The Audit Committee and auditors have raised no comments. General corporate purpose utilisation during the quarter stood at ₹2.25 Crore as on March 31, 2026, directed towards strategic initiatives, marketing and brand building, and general corporate exigencies, among other board-approved purposes. The report was signed by Sakshi Jain, Company Secretary and Compliance Officer, and is available on the company's website at www.groupindogulf.com .

Given that working capital utilisation has already exceeded the proposed amount by ₹3.91 Crore, how might Indogulf Cropsciences fund any additional working capital needs in FY2026-27 without diluting equity or increasing debt?

With only ₹3.40 Crore of the ₹14 Crore allocated for the DF plant at Barwasni deployed by March 2026, what is the revised timeline for completion and how could delays impact the company's production capacity and revenue targets?

How might the maturity of the Vivriti Capital Commercial Paper investment in April 2026 affect the company's redeployment strategy for unutilised IPO proceeds in the upcoming quarters?

More News on Indogulf Cropsciences